TTNP

Titan Pharmaceuticals, Inc. (TTNP) ESG Analysis Analysis (2026)

Invetso Score: 5.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

TTNP shows no disclosed R&D intensity in the provided metrics, which limits evidence of environmental innovation versus peers that report measurable low-carbon or process-efficiency investment.

The absence of disclosed capital-allocation data tied to environmental efficiency leaves its environmental positioning harder to verify than peers with clearer sustainability-linked spending disclosures.

No direct environmental liabilities, emissions, or resource-use metrics were provided, so the company cannot be assessed as structurally better or worse than peers on this basis.

Relative to peers in regulated industries, the available disclosure set is thin, which constrains confidence in environmental oversight rather than indicating a clear environmental advantage.

Social

Score:

The provided metrics do not include workforce, safety, or customer-impact indicators, so TTNP’s social positioning cannot be shown to exceed peers on disclosed evidence.

Zero reported stock-based compensation in the supplied data may reduce dilution-related employee alignment concerns, but it does not establish stronger social practices than peers.

No controversy, litigation, or human-capital disclosure was provided, leaving social risk assessment dependent on limited evidence rather than demonstrated peer outperformance.

Compared with peers that disclose retention, training, and safety metrics, TTNP’s sparse social disclosure weakens transparency and limits relative ESG strength.

Governance

Score:

The supplied leverage metrics show debt-to-equity at zero and net debt to EBITDA near 0.13, which suggests a comparatively conservative balance-sheet posture versus leveraged peers.

Zero stock-based compensation in the provided data may indicate lower equity-dilution pressure, but it also limits insight into executive incentive design relative to peers.

No board, audit, ownership, or controversy data were provided, so governance strength cannot be confirmed beyond the limited capital-structure signals available.

Relative to peers, the main governance support comes from low leverage, while the absence of broader governance disclosure prevents a stronger score.

Overall Score

Score:

TTNP’s ESG profile is best characterized by limited disclosure and a modest governance advantage from low leverage, while environmental and social positioning remain unproven versus peers.

Score Driver: Sparse ESG Disclosure Across Environmental And Social Dimensions

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Titan Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →